Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 2/20 | 0.49 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30081454 | 1.00 | HSD17B1 (0.49) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL5372286 | 0.86 | MEN1 (0.55) | HSD17B1MEN1MAPK1KMT2ANPSR1 | |
| SCHEMBL30957305 | 0.83 | CASP1 (0.50) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL14430312 | 0.83 | HSD17B1 (0.44) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL21505155 | 0.83 | CASP1 (0.50) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL25269929 | 0.83 | HSD17B1 (0.60) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL4808913 | 0.83 | HSD17B1 (0.44) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL7894570 | 0.83 | HSD17B1 (0.44) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL30042961 | 0.83 | HSD17B1 (0.44) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL29033 | 0.83 | HSD17B1 (0.60) | HSD17B1PBRM1CASP1CASP7HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114094016-B | Organic photoelectric synaptic device and its sound recognition method | 中国科学院大学 | 2025-06-03 | — | — | CN | claimed |
| CN-119638725-A | Non-condensed ring electron acceptor containing asymmetric side chain and preparation method and application thereof | 江西优宝新材料科技有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-116063278-B | Near infrared organic electronic receptor and preparation method and application thereof | 浙江大学 | 2024-02-02 | — | — | CN | claimed |
| CN-116063278-A | Near infrared organic electronic receptor and preparation method and application thereof | 浙江大学 | 2023-05-05 | — | — | CN | claimed |
| CN-114094016-A | Organic photoelectric synapse device and sound identification method thereof | 中国科学院大学 | 2022-02-25 | — | — | CN | claimed |
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12486269-B2 | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity | ACONCAGUA BIO, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250257067-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO, INC. | 2025-08-14 | — | — | US | disclosed |
| CN-115991713-B | Near infrared two-region luminescent compound, aggregate, preparation method and application thereof | 香港中文大学（深圳） | 2025-06-20 | — | — | CN | disclosed |
| CN-114094016-B | Organic photoelectric synaptic device and its sound recognition method | 中国科学院大学 | 2025-06-03 | — | — | CN | disclosed |
| CN-119638725-A | Non-condensed ring electron acceptor containing asymmetric side chain and preparation method and application thereof | 江西优宝新材料科技有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-12145929-B2 | Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same | NEXTGEN BIOSCIENCE CO., LTD. (KR) | 2024-11-19 | — | — | US | disclosed |
| EP-0657426-B1 | Tricyclic pyrrole derivatives | HOFFMANN LA ROCHE (CH) | 1998-07-22 | — | — | EP | disclosed |
| US-5719280-A | REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID | SYNTEX (U.S.A.) INC. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5646173-A | ANTISEROTONINE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1997-07-08 | — | — | US | disclosed |
| CN-1151735-A | Benzocycloalkylazolethione derivatives | SYNTEX INC (US) | 1997-06-11 | — | — | CN | disclosed |
| EP-0757677-A1 | BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | disclosed |
| WO-1995029165-A2 | BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-11-02 | — | — | WO | disclosed |
| EP-0657426-A2 | Tricyclic pyrrole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486269-B2 | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity | IAPP, GIPR, SCTR | HSD17B1 3051/4885PBRM1 2661/4885CASP1 2652/4885 |
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | NPY1R, CALCRL, SCTR | HSD17B1 732/4885PBRM1 1377/4885CASP1 1170/4885 |
| US-20250257067-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | IAPP, GIPR, SCTR | HSD17B1 3051/4885PBRM1 2661/4885CASP1 2652/4885 |
| US-12145929-B2 | Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same | ENPP2, UACA, ACAT2 | HSD17B1 4030/4885PBRM1 4014/4885CASP1 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.